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983Catheter ablation has dramatically changed themanagement of
atrial ﬁbrillation (AF) and is currently a standard-of-care
treatment option for drug-refractory symptomatic AF (1).
Over the past decade, AF ablation has been increasingly per-
formed and is one of the most commonly performed ablation
procedures in many electrophysiology laboratories across the
world. AF ablation is a relatively complex procedure involving
multiple critical steps which can pose a potential risk for both
bleeding and thromboembolic complications (2–4). With
improved techniques and experience, the incidence of peri-
procedural complications has decreased. Nevertheless, major
procedural complications, especially bleeding and thrombo-
embolic complications, result in signiﬁcant morbidity and
mortality (4). Minimizing these complications with optimal
periprocedural anticoagulation with an appropriate balance
between bleeding and thrombosis is critical to the safety of the
procedure.
There is increasing evidence for the superiority of unin-
terrupted warfarin therapy, with a target international
normalized ratio (INR) between 2 and 3, as a periprocedural
anticoagulant, compared to other interrupted anticoagulation
strategies (5–9). In the last few years, increasingly more AF
patients are maintained on newer anticoagulant agents,
posing a management challenge for periprocedural anti-
coagulation when patients are scheduled for AF ablation
(10). Recent studies evaluating the role of dabigatran, a new
oral direct thrombin inhibitor, have yielded mixed results
(11–15). Rivaroxaban, a direct factor Xa inhibitor, another
new oral anticoagulant, was approved for the prevention of
thromboembolism in patients with nonvalvular AF in
November 2011 (16). Very limited data are available on the
role of rivaroxaban as a periprocedural anticoagulant for AF
ablation (17,18). Recent post hoc analysis of ROCKET AF
(An Efﬁcacy and Safety Study of Rivaroxaban With
Warfarin for the Prevention of Stroke and Non-Central
Nervous System Systemic Embolism in Patients With
Non-Valvular Atrial Fibrillation) trial comparing the out-
comes of patients who underwent electrical cardioversion,
chemical cardioversion, and AF ablation in randomized
groups of warfarin and rivaroxaban therapy did not ﬁnd any
signiﬁcant differences in the bleeding or thromboembolic
complication rates between the groups (18). However, only
half of the patients in the rivaroxaban group who underwent
AF ablation took the drug on the day of the procedure, and
further details of the periprocedural anticoagulation regimen
are lacking. Eitel et al. (17) reported the outcomes of
AF ablation using novel anticoagulants. Patients in the
rivaroxaban group received a dose of the drug on the morning
prior to the procedure, and the drug was continued on the
evening of the procedure. No periprocedural complications
were noted in the group. However, the study wasScientiﬁc, St. JudeMedical, and Biotronik. All other authors have reported that they have
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accepted November 19, 2013.signiﬁcantly limited by the sam-
ple size, with only 13 patients in
the rivaroxaban group. A study
systematically evaluating the role
of continuous rivaroxaban as a
periprocedural anticoagulant dur-
ing AF ablation in comparison
with continuous warfarin is lack-
ing. We intended to evaluate the
safety and feasibility of rivarox-
aban as a periprocedural antico-
agulant in patients undergoing
AF ablation.
Methods
We performed a multicenter, ob-
servational study from a pro-
spectively collected registry of
AF patients undergoing radio-
frequency catheter ablation at 8
institutions in North America
between January 2012 andMarch
2013. The study protocol was
approved by the institutional re-
view boards at the respective in-
stitutions. The rivaroxaban group
consisted of all consecutive pa-
tients who had been taking rivar-
oxaban once daily for at least 30
days prior to the catheter ablation
procedure. The warfarin group
consisted of an equal number of
patients, matched for age, sex,
and type of AF, undergoing AF
ablation and taking uninterrupted
warfarin during the same time
period. All patients who were receiving uninterrupted
warfarin therapy for 30 days, regardless of the INR value at the
time of the procedure, were included in the study. Only pa-
tients who underwent manual, radiofrequency catheter abla-
tion were included in the study, and patients who underwent
cryoballoon ablation or remote navigation-aided ablation
were excluded from the study.
Periprocedural anticoagulation regimen. Rivaroxaban is
prescribed at doses of 15 to 20 mg as a once-daily medica-
tion to be taken with the evening meal (19). Patients were
asked to take their rivaroxaban dose, as scheduled, on the
evening prior to the procedure. None of the patients in the
rivaroxaban group was bridged with unfractionated or low-
molecular-weight heparin periprocedurally. All patients in
the rivaroxaban group underwent transesophageal echocar-
diography (TEE) on the morning of the procedure. Rivar-
oxaban administration was resumed on the evening of the
procedure, with a minimum posthemostasis period of 3 h.
Therefore, it was a completely uninterrupted rivaroxaban
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984therapy regimen. In the warfarin group, AF ablation was
performed without any interruption of warfarin. Outpatient
monitoring of INR was performed once weekly for at least 3
weeks prior to the procedure to ensure therapeutic anti-
coagulation (INR between 2 and 3). Patients in the warfarin
group with a therapeutic INR level did not undergo TEE.
Seven patients (2%) in the uninterrupted warfarin group had
an INR of <2.0 on the morning of the procedure and un-
derwent TEE prior to the procedure; 3 of them were
receiving an unfractionated heparin (UH) drip post-
procedure. All 7 patients had therapeutic INR on the next
morning and were discharged home without any additional
anticoagulation bridge.
Ablation procedure. Patients underwent pulmonary vein
antral isolation (PVAI) with a double trans-septal approach
as described in detail elsewhere (20). Brieﬂy, with the help of
intracardiac echocardiography, two trans-septal accesses
were obtained using standard needles and sheaths. The site,
size, and number of venous sheaths and recording catheters
was left to the operator’s preference. A bolus of 10,000 U of
UH was administered just prior to trans-septal puncture.
Activated clotting time (ACT) was measured 15 min after
the administration of bolus dose and after every 20 min
subsequently. For the duration of the procedure when
catheters were in the left atrium (LA), weight-adjusted
boluses of UH were administered to keep ACT between
300 and 400 s; the LA was mapped using a circular mapping
catheter (Lasso, Biosense Webster Inc., Diamond Bar,
California; or Spiral, St. Jude Medical, Minneapolis, Min-
nesota). Electrical isolation was accomplished by ablating
the antrum of pulmonary veins with 3.5-mm open irrigated
tip catheter (ThermoCool, Biosense Webster Inc.). For
ablating anterior segments, radiofrequency energy up to a
maximum range of 40 to 45 W was used, whereas 25 to
35 W of radiofrequency output was used to ablate posterior
segments. The numbers of lesions and lesion sets were
determined by the operator, depending on each patient’s
arrhythmia substrate. Intravenous adenosine was used to
conﬁrm PV isolation in some patients.
Only PVAI was performed in patients with paroxysmal
AF. The endpoint of this ablation procedure was to
accomplish entry and exit blockages. In cases of persistent
AF, additional substrate modiﬁcation using complex frac-
tionated electrograms (CFAEs) was also performed.
CFAEs were identiﬁed with a mapping catheter on the
three-dimensional map along different regions within the
atria (posterior wall, left atrial septum, left atrial roof,
coronary sinus, left atrial appendage base, and crista ter-
minalis) and later ablated. In case of spontaneous intra-
atrial tachycardia during the ablation procedure, it was
mapped and ablated. In addition to PVAI and ablation of
CFAEs, ablation of residual LA tachycardia with roof lines
and a mitral isthmus line along with LA appendage and
coronary sinus isolation were done in some patients at the
operator’s discretion. If mapping showed double potentials
around the junction of superior vena cava and right atrium,then additional ablation was done in the region. Further-
more, 20 mg/min isoproterenol was given for 15 min to
identify nonpulmonary vein triggers, and ablation of these
triggers was performed. If PVAI and substrate modiﬁca-
tion did not achieve sinus rhythm, direct current cardio-
version was performed to restore sinus rhythm.
Data collection. All participating centers had an AF reg-
istry in their respective institutions, where demographic,
clinical, procedural, and complications data were collected
prospectively. Another common database speciﬁc to this
study was created centrally and was updated frequently by
each of the participating institutions prospectively. All
complications occurring within the ﬁrst 30 days after the
ablation procedure were included in the study database. Data
for complications were collected during the hospital stay, at
1-month follow-up visits, or by 30-day telephone interview.
No patients were lost to follow-up.
Safety endpoints. Pericardial effusions and hematomas
were identiﬁed as bleeding complications. Transient ischemic
attacks (TIA) and cerebrovascular accidents were identiﬁed as
thromboembolic events after intracranial bleeding was ruled
out. Major bleeding was deﬁned as any bleeding severe
enough to require blood transfusion, hematomas requiring
surgical intervention, and pericardial bleeding necessitating
drainage (cardiac tamponade). Small hematomas and peri-
cardial effusion which did not require any intervention were
considered minor bleeding complications. Occurrences of
pericardial effusion that occurred more than 48 h post-
procedure and required drainage were considered late peri-
cardial effusion. Other complications related to the procedure
but unrelated to anticoagulation were also noted.
Statistical analysis. Study populations included the “rivar-
oxaban” group and the “warfarin” group, each with an equal
number of patients, matched by age, sex, type of AF, and the
institution at which the ablation was performed. A difference
of 3% in the incidence of major hemorrhage was considered
clinically meaningful. With a noninferiority margin of 3%, a
2-sided type 1 error of 0.05, and 80% power, the required
sample size per group was determined to be 305.
Categorical variables were compared using either the chi-
square test or Fisher exact test where appropriate, and
continuous variables were compared using Student t-test or
Wilcoxon rank sum model where necessary. Baseline de-
mographics, procedural variables, and periprocedural com-
plications were compared between the 2 groups. Univariate
analyses were performed to identify the predictors of peri-
procedural complications. A p value of <0.05 (2-sided) was
considered statistically signiﬁcant. All analyses were per-
formed with IBM SPSS version 20.0 software (SPSS, Inc.,
Chicago, Illinois) for Windows (Microsoft, Redmond,
Washington).
Results
Until March 2013, 321 patients underwent AF ablation on
uninterrupted rivaroxaban in the participating centers. An
Table 2
Comparison of Procedural Variables Between Patients
on Rivaroxaban and Warfarin
Procedural Variables
Group
p Value
Rivaroxaban
(N ¼ 321)
Warfarin
(N ¼ 321)
Sinus rhythm on arrival at the
laboratory (%)
209 (65) 228 (71) 0.110
Ablation of CFAE/posterior wall 116 (36) 125 (39) 0.463
Additional linear lesions including
right atrium (%)
101 (31) 118 (37) 0.157
Cardioversion during procedure (%) 102 (32) 90 (28) 0.300
Acute PV Isolation (%) 317 (99) 314 (99) 1.00
Procedural time, min 195  62 198  66 0.550
Fluoroscopy time, min 49  20 51  30 0.320
RF time, min 56  25 58  29 0.349
Values are n (%) or mean  SD.
AF ¼ atrial ﬁbrillation; AFL ¼ atrial ﬂutter; CFAE ¼ complex fractionated atrial electrograms;
PV ¼ pulmonary vein; RF ¼ radiofrequency.
Table 1
Comparison of Baseline Demographics, Clinical
Parameters, and Medication Use Between Patients
on Rivaroxaban and Warfarin
Baseline Characteristic
Group
p Value
Rivaroxaban
(N ¼ 321)
Warfarin
(N ¼ 321)
Mean age (yrs) 63  10 63  10 0.98
Mean body mass index
(kg/m2)
30  6 30  6 0.162
Male (%) 221 (69) 221 (69) 1.00
Caucasian (%) 277 (86) 292 (91) 0.06
Paroxysmal atrial ﬁbrillation
(%)
164 (51) 164 (51) 1.00
Duration of atrial ﬁbrillation,
months
42 (20–81) 48 (22–84) 0.243
Re-do procedure (%) 88 (27) 74 (23) 0.203
Heart failures (%) 30 (7) 23 (6) 0.315
Hypertension (%) 177 (55) 199 (62) 0.078
Age >75 yrs (%) 41 (13) 41 (13) 1.00
Diabetes (%) 59 (18) 64 (20) 0.616
Transient ischemic attacks
or stroke (%)
34 (11) 26 (8) 0.278
Coronary artery disease (%) 60 (19) 67 (21) 0.488
Peripheral artery disease (%) 17 (5) 25 (8) 0.202
Sleep apnea (%) 74 (23) 79 (25) 0.643
Chronic obstructive pulmonary
disease (%)
24 (8) 30 (9) 0.414
Chronic renal insufﬁciency (%) 8 (3) 9 (3) 1.00
Serum creatinine 0.845  0.25 0.874  0.23 0.126
CHADS2 score 1.16  1.0 1.18  1.0 0.876
Median CHADS2 score 1 (0–2) 1 (0–2) 0.737
CHA2DS2VASc score 2.17  1.6 2.21  1.5 0.781
Median CHA2DS2VASc score 2 (1–3) 2 (1–3) 0.808
HAS-BLED score 1.47  0.9 1.70  1.0 0.032
Left atrial size, cm 4.4  0.8 4.3  0.8 0.114
% of left ventricular ejection
fraction
58  8 57  8 0.184
Aspirin (%) 98 (31) 84 (26) 0.220
Clopidogrel (%) 22 (7) 15 (5) 0.236
Beta blocker (%) 186 (58) 192 (60) 0.630
Calcium channel blocker (%) 90 (27) 74 (23) 0.148
Values are mean  SD, n (%), or median (interquartile range).
CHADS2 ¼ congestive heart failure, hypertension, age, diabetes mellitus, and prior stroke,
transient ischemic attack, or thromboembolism; CHA2DS2VASc ¼ congestive heart failure, hyper-
tension, age, diabetes mellitus, and prior stroke, transient ischemic attack, or thromboembolism,
vascular disease; HAS-BLED ¼ hypertension, abnormal renal/liver function, stroke, bleeding history
or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly.
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985equal number of patients who underwent AF ablation while
taking uninterrupted warfarin were matched by age, sex, and
type of AF and were included in the current study of 642
patients (321 in each group).
Baseline and procedural characteristics. Mean age of the
study population was 63  10 years, with 442 (69%) males
and 328 (51%) patients who had paroxysmal AF with no
differences between the groups as shown in Table 1. There
were no differences between mean body mass index, mean
AF duration, proportion of re-do procedures, prevalence of
advanced age (>75 years), hypertension, diabetes, prior
stroke and/or TIA, coronary artery disease, sleep apnea,
chronic obstructive pulmonary disease, chronic renalinsufﬁciency, LA size and left ventricular ejection fraction
between the groups. The mean CHADS2 (congestive heart
failure, hypertension, age, diabetes mellitus, and prior stroke,
transient ischemic attack, or thromboembolism) score
(1.17  1.0) and mean CHA2DS2VASc (congestive heart
failure, hypertension, age, diabetes mellitus, and prior stroke,
transient ischemic attack, or thromboembolism, vascular
disease) score (2.19  1.6) were not different between both
the groups. Patients in the rivaroxaban group had a lower
HAS-BLED (hypertension, abnormal renal/liver function,
stroke, bleeding history or predisposition, labile international
normalized ratio, elderly, drugs/alcohol concomitantly) score
(1.47  0.9 vs. 1.70  1.0, respectively; p ¼ 0.032). There
were no differences in the usage of medications, including
aspirin and clopidogrel.
The dose of rivaroxaban was 20 mg/day in 315 patients
and 15 mg/day in the other 6 patients. The mean time from
the last dose of rivaroxaban to the start of the procedure was
16  5 h. The mean time for resumption of the dose was
5.6  2 h posthemostasis. The mean INR in the rivaroxaban
group (available in 180 patients) was 1.41  0.5 compared to
a mean INR of 2.33  0.4 (p < 0.001) in the warfarin
group. Seven (3%) patients taking uninterrupted warfarin
had an INR of <2.0 on the morning of the procedure
(all, 1.7). There were no signiﬁcant differences between
the creatinine and procedural variables in either group, as
shown in Tables 1 and 2, respectively. Procedure time,
ﬂuoroscopy time, and ablation time were not signiﬁcantly
different between the 2 groups.
Complications. A total of 47 patients (7.3%) had a
bleeding complication and 2 patients (0.3%) had TIAs in
the entire study population, as shown in Table 3. There were
no differences in major bleeding complications (5 [1.6%] vs.
7 [2.2%], respectively; p ¼ 0.772), minor bleeding compli-
cations (16 [5.0%] vs. 19 [5.9%], respectively; p ¼ 0.602),
or embolic complications (1 [0.3%] vs. 1 [0.3%], respec-
tively; p ¼ 1.00) in the rivaroxaban group compared to the
warfarin group. The composite of thromboembolic and
Table 3
Comparison of Complications between Rivaroxaban
and Warfarin
Complication
Rivaroxaban
(N ¼ 321)
Warfarin
(N ¼ 321)
Total
(N ¼ 642) p Value
Major bleeding (%) 5 (1.6) 7 (2.2) 12 (1.9) 0.772
Early cardiac
tamponade (%)
2 (0.6) 4 (1.2) 6 (0.9)
Delayed cardiac
tamponade (%)
1 (0.3) 0 (0) 1 (0.2)
Moderate access site
hematomas (%)
2 (0.6) 3 (0.9) 5 (0.8)
Minor bleeding
complications (%)
16 (5.0) 19 (5.9) 35 (5.5) 0.602
<Moderate access site
hematoma (%)
13 (4.0) 18 (5.6) 31 (4.8)
Insigniﬁcant pericardial
effusions (%)
3 (0.9) 1 (0.3) 4 (0.6)
All bleeding
complications (%)
21 (6.5) 26 (8.1) 47 (7.3) 0.449
Thromboembolic
complications
(stroke/TIA) (%)
1 (0.3) 1 (0.3) 2 (0.3) 1.00
TIA (%) 1 (0.3) 1 (0.3) 2 (0.3)
Stroke 0 0 0
Bleeding and
thromboembolic
complications (%)
22 (6.8) 27 (8.4) 49 (7.6) 0.457
Other complications 3 (0.9) 2 (0.6) 5 (0.8) 1.00
Values are n (%).
TIA ¼ transient ischemic attack.
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986bleeding complications was not signiﬁcantly different in the
rivaroxaban group compared to the warfarin group (22
[6.8%] vs. 27 [8.4%], respectively; p ¼ 0.457). Three pa-
tients in the rivaroxaban group and 4 patients in the warfarin
group underwent emergent percutaneous pericardial
drainage with no sequelae. None of the patients required
surgical drainage. Anticoagulation reversal was attempted in
2 patients on rivaroxaban therapy (with fresh frozen plasma
and activated factor VII, respectively). All 4 patients on
warfarin therapy underwent emergent reversal of anti-
coagulation with fresh frozen plasma and vitamin K. Anti-
coagulation could be resumed in all patients prior to
discharge. The patient in the warfarin group who had a
postprocedural TIA had an INR of 1.8 on the morning of
the procedure. After the procedure, the patient underwent
UH anticoagulation therapy for 1 day, at which point the
INR came back into the therapeutic range and the patient
was discharged home with no additional anticoagulation. No
patient in either group had a periprocedural stroke or death.Discussion
Main study ﬁndings. In our multicenter, observational
study, we found that uninterrupted rivaroxaban is as safe and
efﬁcacious in preventing periprocedural bleeding and
thromboembolic events during AF ablation as uninterrupted
warfarin therapy. This is the ﬁrst study to evaluate the
feasibility and safety of using continuous rivaroxaban as a
periprocedural anticoagulant during AF ablation.Thromboembolic and bleeding complications after AF
ablation. Bleeding and thromboembolic events are the
most common complications of AF ablation (4,21–26).
Major bleeding complications are the cause of 25% of all
deaths related to AF ablation. The complexity of the integral
components of the procedure, including trans-septal punc-
ture, LA cannulation by multiple large sheaths and catheters,
intraprocedural anticoagulation, extensive ablation with
activation of a cascade of inﬂammatory responses on an
already diseased LA, inherently exposes the patient to an
unavoidable complication risk. The evolution of the proce-
dure over the past decade, in multiple fronts, has decreased
the risk of these complications signiﬁcantly (5,24,27).
One such important evolutionary aspect is periprocedural
anticoagulation.
Periprocedural anticoagulation. Currently, intraprocedural
use of UH to keep ACTs in the range of 300 to 400 s is a
routine approach in almost all centers regardless of the back-
ground anticoagulation (1). However, pre- and postprocedural
anticoagulation strategies seem to be still signiﬁcantly variable
in different institutions (28). Several different anticoagulation
protocols consisting of varied combinations of antiplatelet
agents, warfarin, and unfractionated and low-molecular-
weight heparin combined with TEE screening stratiﬁed by
baseline risk of systemic thromboembolism and type of AF
are being used and are subject to some debate (1–3,28).
Operator comfort and experience seem to be the primary
drivers behind the selection of periprocedural anticoagulation
regimen (27).
Uninterrupted warfarin therapy with therapeutic anti-
coagulation has been shown to be associated with lower risk
of periprocedural thromboembolic events after AF ablation
and is increasingly being accepted as the preferred anti-
coagulation strategy (5,7,8,29). However, increasingly more
patients are being treated with newer oral anticoagulants,
thereby complicating the periprocedural anticoagulation
management. In addition, despite being on uninterrupted
warfarin therapy, some patients do have subtherapeutic INR
at the time of the procedure, exposing them to a higher risk
of complications. In our current study, 7 of 321 patients
(2%), despite being on uninterrupted warfarin therapy and
having a close outpatient follow-up, did end up having
subtherapeutic INR on the morning of the procedure.
Moreover, 1 of those 7 patients had a TIA after the pro-
cedure, necessitating additional anticoagulation.
Various protocols have been proposed and have experi-
mented with dabigatran, the ﬁrst of the newer oral antico-
agulants for periprocedural management with mixed results
(11–15). In our previous study, nearly uninterrupted anti-
coagulation with dabigatran (holding the morning dose),
which theoretically has a better protection from periproce-
dural thromboembolism, was associated with both increased
bleeding and thromboembolic events, especially in the
nonparoxysmal AF (11). Other observational studies with a
more interrupted approach showed equivalent bleeding
and embolic events compared to therapeutic warfarin
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987(13,15,30,31). The bleeding risk in our previous study was
likely related to the overlapping pharmacodynamic effect of
UH and dabigatran (32). The higher incidence of throm-
boembolic events in our study was seen exclusively in non-
paroxysmal AF patients (3 of 43 [8%]) and was probably
related to a difference in the patient proﬁle and the ablation
approach. As of now, there is no consensus regarding the
management of patients taking dabigatran who are referred
for AF ablation (28).
An ideal periprocedural anticoagulant for AF ablation, in
addition to being associated with minimal bleeding and
thromboembolic events, should be the same anticoagulant
the patient had been taking prior to the procedure, without
interrupting the patient’s dosing schedule. Rivaroxaban, the
second of the US Food and Drug Administration-approved
newer non-vitamin K antagonist anticoagulants, at a dose of
15 to 20 mg once daily, has been shown to be noninferior to
warfarin in preventing thromboembolic events in patients
with nonvalvular AF and was approved for use in the United
States in November of 2011 (16). Rivaroxaban is an oral,
direct inhibitor of factor Xa that is rapidly absorbed and has
a time to peak plasma concentration of <4 h and a half-life
ranging from 7 to 13 h, depending on the age of the patient
(33,34). By inhibiting the formation of thrombin, it blocks
both intrinsic and extrinsic pathways and is known to be
associated with elevated INR (35). The mean INR in our
rivaroxaban group was also slightly high, as seen in prior
studies (36). As a once-a-day dosing medication, rivarox-
aban can be used in the AF ablation periprocedural setting
without interrupting the patient’s regular dosing schedule. It
is a potentially attractive alternative to warfarin if consis-
tently shown to be safe in this setting.
Piccini et al. (18) recently reported a post hoc analysis of
ROCKET AF trial results, comparing the outcomes of
patients who underwent electrical cardioversion, chemical
cardioversion, and AF ablation in randomized groups
receiving warfarin or rivaroxaban therapy. The study lacked
the critical details of peri-AF ablation anticoagulation
management to draw any meaningful conclusions about the
relative efﬁcacy of either of the agents in AF ablation.
Almost all the comparative analyses were made after pooling
patients undergoing chemical cardioversion, electrical car-
dioversion, and AF ablation. Although the study compared
the outcomes between the groups, only 49% of the patients
in the rivaroxaban group were taking the drug on the day of
the procedure. In addition, few patients underwent bridging
with low- molecular-weight heparin. Eitel et al. (17) re-
ported outcomes of using novel oral anticoagulants in the
periprocedural setting of AF ablation. Of the 259 patients
included in the study, 13 were receiving rivaroxaban both
before and after the procedure, and an additional 3 patients
were started on rivaroxaban after the procedure. The pa-
tients underwent some interruption of rivaroxaban, resulting
in a change in the dosing time from morning (prior to the
day of the procedure) to an evening dosing time (post-
procedure). None of the 16 patients had any bleeding orthromboembolic complications. A randomized controlled
trial comparing uninterrupted warfarin with uninterrupted
rivaroxaban therapy for AF ablation (VENTURE-AF [Study
Exploring Two Treatment Strategies in Patients With Atrial
Fibrillation Who Undergo Catheter Ablation Therapy] trial)
in patients with patients with atrial ﬁbrillation is underway
and hopefully will give us more insights into the role of
this newer agent in this important setting of AF ablation
(37). In our current study, approximately half of the patients
had nonparoxysmal AF, and many of them underwent addi-
tional ablation lesions. Despite such additional ablation,
unlike our prior experience with dabigatran, we did not
notice any increased incidence of thromboembolic compli-
cations, which is very reassuring.
As with dabigatran, rivaroxaban also does not have a
speciﬁc antidote at this time. Concerns about management of
life-threatening hemorrhagic complications, especially in the
periprocedural setting, do exist. Prothrombin complex
concentrate can reverse some of the anticoagulant action of
rivaroxaban in healthy volunteers (38). However, its role in
clinical hemorrhagic settings has not been systematically
evaluated. In our study, 3 patients taking rivaroxaban re-
quired pericardiocentesis, with no signiﬁcant issues with
excessive bleeding. Speciﬁc antidotes to these newer antico-
agulants are eagerly awaited, especially for use in the peri-
procedural settings.
Study limitations. Our study has the inherent limitations
of a multicenter observational study. The procedural tech-
niques were operator-dependent, which could potentially
confound the results, even though all our centers predom-
inantly practice a similar protocol. We report only 30-day
follow-up outcomes, and longer term outcomes may not be
the same. However, most of the periprocedural complica-
tions occurred during this time frame. The CHADS2 and
CHA2DS2Vasc scores of the patients in our study were
more reﬂective of real-world experience, and we cannot
extrapolate to very-high stroke risk patients. Nevertheless,
lack of data on the feasibility and safety of uninterrupted
rivaroxaban therapy during AF ablation procedure makes
our study very important to the current electrophysiology
practice, especially with increasing use of rivaroxaban in
clinical practice.Conclusions
In our multicenter experience, uninterrupted rivaroxaban
appears to be a feasible and safe alternative to uninterrupted
warfarin therapy in patients undergoing AF ablation. Future
larger and randomized trials are needed to conﬁrm our
ﬁndings.
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